Dendritic cell vaccination in acute myeloid leukemia

Cytotherapy

Volumn 14, Issue 6, 2012, Pages 647-656

  Anguille, Sébastien ^a,b   Willemen, Yannick ^a   Lion, Eva ^a   Smits, Evelien L ^a,b   Berneman, Zwi N ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acute; Dendritic cells; Immunotherapy; Myeloid leukemia; Vaccination

Indexed keywords

DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; IN VITRO STUDY; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTOPENIA; TUMOR IMMUNITY;

EID: 84862223765     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2012.693744     Document Type: Review

References (75)

1. Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VFI. Dendritic cell vaccine therapy for acute myeloid leukemia. Questions and answers. Human Vaccines. 2011;7: 579-84.
2. Smits E, Berneman ZN, Van Tendeloo VFI. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist. 2009;14:240-52.
3. Barrett AJ, Le Blanc K. Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol. 2010;161:223-32.
4. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol. 2007;82:1365-74. (Pubitemid 350276946)
5. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science. 2001;293:251-3. (Pubitemid 32694732)
6. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol. 2006;6:476-83.
7. Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med. 2009;7:109.
8. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265-77.
9. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specifi c immunotherapeutic approaches. Blood. 2006;108:4109-17. (Pubitemid 44913282)
10. Alatrash G, Molldrem JJ. Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol. 2011;4:37-50.
11. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol. 2005;5:112-24. (Pubitemid 40208901)
12. Moretta L, Ferlazzo G, Bottino C, Vitale M, Pende D, Mingari MC, et al. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev. 2006;214: 219-28. (Pubitemid 44707913)
13. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503-10. (Pubitemid 351560519)
14. L i L, Reinhardt P, Schmitt A, Barth TFE, Greiner J, Ringhoffer M, et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother. 2005;54:685-93. (Pubitemid 40884165)
15. van den Ancker W, van Luijn MM, Westers TM, Bontkes HJ, Ruben JM, de Gruijl TD, et al. Recent advances in antigenloaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy. 2010;2:69-83.
16. Cignetti A, Vallario A, Roato I, Circosta P, Allione B, Casorzo L, et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that effi ciently stimulate T cell responses. J Immunol. 2004;173:2855-65. (Pubitemid 39063148)
17. van de Loosdrecht AA, van den Ancker W, Houtenbos I, Ossenkoppele GJ, Westers TM. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications. Handb Exp Pharmacol. 2009:319-48.
18. Kremser A, Dressig J, Grabrucker C, Liepert A, Kroell T, Scholl N, et al. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J Immunother. 2010;33:185-99.
19. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. Immunobiology. 2006;211:677-85.
20. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA, Hess CJ, Waisfi sz Q. Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells. Leukemia. 2006;20:1892-5. (Pubitemid 44575003)
21. Roddie PH, Turner ML. Leukemic blasts from patients with karyotypically poor risk AML are resistant to cytokine induced differentiation into dendritic like cells. Blood. 2000;96: 707A-707A.
22. Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, et al. The quality and quantity of leukemiaderived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specifi c T cells. J Immunother. 2010;33:523-37.
23. Narita M, Takahashi M, Liu A, Nikkuni K, Furukawa T, Toba K, et al. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia. Exp Hematol. 2001;29:709-19. (Pubitemid 32500372)
24. Rosenblatt J, Stone R, Wu Z, Vasir B, Deangelo D, Galinsky I, et al. Leukemia derived dendritic cells (LDCs) may be ineffective as a cancer vaccine for acute myeloid leukemia (AML). J Clin Oncol. 2005;23:172S-172S.
25. Curti A, Pandolfi S, Aluigi M, Isidori A, Alessandrini I, Chiodoni C, et al. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. Exp Hematol. 2005;33:1521-30. (Pubitemid 41773852)
26. Fujii S, Shimizu K, Koji F, Kawano F. Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential. J Leukoc Biol. 2003;73:82-90. (Pubitemid 36125678)
27. Curti A, Trabanelli S, Onofri C, Aluigi M, Salvestrini V, Ocadlikova D, et al. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specifi c immune response by inducing potent T regulatory cells. Haematologica. 2010;95:2022-30.
28. Santegoets S, Schreurs MWJ, Masterson AJ, Liu YP, Goletz S, Baumeister H, et al. In vitro priming of tumor-specifi c cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. Cancer Immunol Immunother. 2006;55:1480-90. (Pubitemid 44327836)
29. Yamahira A, Narita M, Nakamura T, Watanabe N, Kaji M, Taniguchi T, et al. Generation of antigen-specifi c cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells. Leuk Res. 2011;35:793-799.
30. Narita M, Watanabe N, Yamahira A, Hashimoto S, Tochiki N, Saitoh A, et al. A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naive T cells. Leuk Res. 2009;33:1224-32.
31. Rasaiyaah J, Noursadeghi M, Kellam P, Chain B. Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukaemia line. Immunology. 2009;127:429-41.
32. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93. (Pubitemid 24181058)
33. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, et al. Pro-infl ammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-42. (Pubitemid 28018007)
34. Van Driessche A, Van de Velde ALR, Nijs G, Braeckman T, Stein B, De Vries JM, et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy. 2009;11:653-68.
35. Kitawaki T, Kadowaki N, Kondo T, Ishikawa T, Ichinohe T, Teramukai S, et al. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide-and keyhole-limpethemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia. Am J Hematol. 2008;83:315-7. (Pubitemid 351458011)
36. Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH, et a l. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher. 2004;19:66-70. (Pubitemid 39006610)
37. Royer PJ, Bougras G, Ebstein F, Leveque L, Tanguy-Royer S, Simon T, et al. Effi cient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy. Exp Hematol. 2008;36:329-39.
38. Lee JJ, Choi BH, Kang HK, Kim SK, Nam JH, Yang DH, et al. Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specifi c T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients. Leuk Res. 2008;32:1653-60.
39. Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, et al. Induction of leukemia-specifi c cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res. 2002;62:2861-8. (Pubitemid 34525772)
40. + T cells against relapsing leukemic cells following allogeneic transplantation by stimulation with leukemic cell-or leukemic lysate pulsed donor cell-derived dendritic cells. Leuk Res. 2004;28:517-24.
41. Draube A, Beyer M, Wolf J. Activation of autologous leukemiaspecifi c T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells. Eur J Haematol. 2008;81: 281-8.
42. Delluc S, Tourneur L, Michallet AS, Boix C, Varet B, Fradelizi D, et al. Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specifi c antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro. Haematol Hematol J. 2005;90:1050-62. (Pubitemid 41323504)
43. Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, Maekawa T, Ohmori K, et al. A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate. Br J Haematol. 2011;153:796-9.
44. Fujii S, Shimizu K, Fujimoto K, Kiyokawa T, Tsukamoto A, Sanada I, et al. Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLAmatched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk Lymphoma. 2001;42: 357-69. (Pubitemid 32725591)
45. + ) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. Exp Hematol. 2011;39:424-433.
46. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother. 2002;51:299-310. (Pubitemid 34743982)
47. Lee JJ, Park MS, Park JS, Kang HK, Kim SK, Pham TNN, et al. Induction of leukemic-cell-specifi c cytotoxic T lym -phocytes by autologous monocyte-derived dendritic cells presenting leukemic cell antigens. J Clin Apheresis. 2006;21:188-94.
48. Schottker B, Schmidt-Wolf IG. Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells. Ger Med Sci. 2011;9: Doc18 according to PubMed.
49. Rosenblatt J, Stone RM, Avivi I, Uhl L, Neuberg D, Joyce R, et al. Clinical trial evaluating DC/AML fusion cell vaccination alone and in conjunction with PD-1 blockade in AML patients who achieve a chemotherapy-induced remission. Blood. 2011;118:432-3.
50. + CD38-acute myeloid leukemia (AML) cells potentiates targeting AML-initiating cells by specifi c CTL induction. J Immunother. 2009;32:408-14.
51. Klammer M, Waterfall M, Samuel K, Turner ML, Roddie PH. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br J Haematol. 2005;129:340-9. (Pubitemid 40646892)
52. Gong JL, Koido S, Kato Y, Tanaka Y, Chen DS, Jonas A, et al. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res. 2004;28:1303-12. (Pubitemid 39314410)
53. Banat GA, Usluoglu N, Hoeck M, Ihlow K, Hoppmann S, Pralle H. Dendritic cells fused with core binding factor-beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes. Br J Haematol. 2004;126:593-601. (Pubitemid 39093103)
54. Van Tendeloo VF, de Velde AV, Van Driessche A, Cools N, Anguille S, Ladell K, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms ' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA. 2010;107:13824-9.
55. DiPersio JF, Collins RH, Blum W, Devetten MP, Stiff P, Elias L, et al. Immune responses in AML patients following vaccination with GRNVAC1, autologous RNA transfected dendritic cells expressing telomerase catalytic subunit hTERT. Blood. 2009;114:262-262.
56. Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF. Dendritic cell-based cancer gene therapy. Hum Gene Ther. 2009;20:1106-18.
57. Weigel BJ, Nath N, Taylor PA, Panoskaltsis-Mortari A, Chen W, Krieg AM, et al. Comparative analysis of murine marrowderived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. Blood. 2002;100:4169-76. (Pubitemid 35396885)
58. Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, et al. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Exp Hematol. 2006;34:1403-12. (Pubitemid 44374832)
59. + hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients. Cancer Res. 1999;59:2150-8. (Pubitemid 29217679)
60. + cord blood cell-derived and irradiated tumor cellprimed dendritic cells. Int J Hematol. 1998;68:169-82. (Pubitemid 28479941)
61. + ) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood. 2002;100: 2858-66.
62. Sanchez J, Herrera C, Torres A, Roman-Gomez J, Alvarez M.A. Chemotherapy plus G-CSF mobilized peripheral blood stem cell harvests from acute myeloid leukaemia patients contain large amounts of polyclonal myeloid lin neg CD11c pos dendritic precursor cells. Br J Haematol. 2004;124:636-44. (Pubitemid 38297097)
63. Serrano-Lopez J, Sanchez-Garcia J, Serrano J, Alvarez-Rivas MA, Garcia-Castellano JM, Roman-Gomez J, et al. Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia. Transfusion. 2011;51: 1546-55.
64. Klangsinsirikul P, Russell NH. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol. 2002;30:495-501. (Pubitemid 34556742)
65. Mohty M, Jarrossay D, Lafage-Pochitaloff M, Zandotti C, Briere F, de Lamballeri XN, et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood. 2001;98:3750-6.
66. Fujii S, Hamada H, Fujimoto K, Shimomura T, Kawakita M. Activated dendritic cells from bone marrow cells of mice receiving cytokine-expressing tumor cells are associated with the enhanced survival of mice bearing syngeneic tumors. Blood. 1999;93:4328-35. (Pubitemid 29279276)
67. Pawlowska AB, Hashino S, McKenna H, Weigel BJ, Taylor PA, Blazar BR. In vitro tumor-pulsed or in vivo Flt3 ligandgenerated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Blood. 2001;97:1474-82. (Pubitemid 32183775)
68. Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A, et al. Phase I/II study of vaccination with dendriticlike leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol. 2006;133:152-7.
69. Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol. 2006;28:855-61.
70. Khoury HJ, Collins RH, Blum W, Maness L, Stiff P, Kelsey SM, et al. Prolonged administration of the telomerase vaccine GRNVAC1 is well tolerated and appears to be associated with favorable outcomes in high-risk acute myeloid leukemia (AML). Blood. 2010;116:904-904.
71. + T cells preferentially reside in the bone marrow. Blood. 2009;113:2238-44.
72. Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev. 2010;234:199-212.
73. Anguille S, Lion E, Willemen Y, Van Tendeloo VF, Berneman ZN, Smits EL. Interferon-alpha in acute myeloid leukemia: an old drug revisited. Leukemia. 2011;25:739-748.
74. Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. Leukemia. 2012 DOI: 10.1038/leu.2012.87.
75. Berneman ZN, Van de Velde A, Anguille S, Cools N, Van Driessche A, Vermeulen K, et al. WT1-targeted dendritic cell vaccination as a post-remission treatment to prevent full relapse in acute myeloid leukemia. Blood. 2010;116:12-3.